GlassScriptPhysician profile
John Y Sunew
NPI 1932147303
$8,666.71
in general payments reported to CMS, 2019-2025
30 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,844 · 2020: $2,303 · 2021: $694 · 2022: $748 · 2023: $624 · 2024: $853 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,019.93 | 2019-2020 | |
| Ekos Corporation | $1,146.15 | 2019 | |
| Amgen INC. | $934.11 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $642.42 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $580.71 | 2019-2025 | |
| Boston Scientific Corporation | $349.79 | 2019-2024 | Varithena Administration Pack, Watchman Flx |
| Merck Sharp & Dohme LLC | $346.41 | 2022-2025 | Verquvo, Lagevrio |
| Astrazeneca Pharmaceuticals LP | $313.04 | 2019-2024 | |
| Biocompatibles, INC. | $292.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $286.18 | 2019-2025 | Camzyos |
| Abiomed | $264.46 | 2023-2024 | Impella |
| Edwards Lifesciences Corporation | $208.40 | 2019 | |
| Impulse Dynamics (USA) INC. | $175.93 | 2022 | |
| Pfizer INC. | $172.64 | 2019-2025 | |
| Abbott Laboratories | $154.72 | 2019-2024 | Jot Dx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.08 | 2019-2023 | Jardiance |
| Abbvie INC. | $102.60 | 2023 | Dalvance |
| Bard Peripheral Vascular, INC. | $101.75 | 2021-2025 | Venclose Maven Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.54 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $54.06 | 2019-2020 | |
| Inspire Medical Systems, INC. | $46.92 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $42.93 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $41.20 | 2024 | Arcalyst |
| Biotronik INC. | $37.76 | 2019 | |
| Chiesi USA, INC. | $36.52 | 2020-2025 | Kengreal |
| Esperion Therapeutics, INC. | $30.25 | 2025 | Nexletol |
| Genzyme Corporation | $25.00 | 2022 | |
| Venclose INC. | $24.60 | 2020 | |
| Scpharmaceuticals INC. | $22.17 | 2025 | |
| Cardiva Medical, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sunew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.